Company: ARWR
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038858
Chunk: 15

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
 133,352 118,260 Other comprehensive income (loss), net of tax:Unrealized gains on available-for-sale securities876 249 1,022 2,374 Foreign currency translation adjustments91 (141)(415)(139)Comprehensive (loss) income$(177,685)$(173,869)$14,600 $(434,114)

The accompanying notes are an integral part of these unaudited consolidated financial statements. 

2

Arrowhead Pharmaceuticals, Inc.

Consolidated Statements of Stockholders’ Equity 

(in thousands)

(unaudited)

CommonStockAmount ($)AdditionalPaid-InCapitalAccumulated Other Comprehensive IncomeAccumulatedDeficitNon-controlling InterestTotalBalance at September 30, 2024124,376 $217 $1,806,000 $4,750 $(1,625,523)$5,619 $191,063 Stock-based compensation— — 15,209 — — — 15,209 Exercise of stock options70 — 634 — — — 634 Common stock - restricted stock units vesting209 — — — — — — Issuance of pre-funded warrants— — 25,000 — — — 25,000 Foreign currency translation adjustments— — — (106)— — (106)Unrealized losses on available-for-sale securities— — — (507)— — (507)Net loss— — — — (173,085)(2,133)(175,218)Balance at December 31, 2024124,655 $217 $1,846,843 $4,137 $(1,798,608)$3,486 $56,075 Stock-based compensation— — 16,027 — — — 16,027 Exercise of stock options353 — 2,619 — — — 2,619 Common stock - restricted stock units vesting1,128 1 — — — — 1 Common stock issued11,926 12 241,375 — — — 241,387 Foreign currency translation adjustments— — — (400)— — (400)Unrealized gains on available-for-sales securities— — — 653 —